Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,579 shares of the company’s stock after selling 539 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Medpace were worth $857,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. R Squared Ltd purchased a new stake in Medpace during the 4th quarter worth approximately $30,000. SBI Securities Co. Ltd. acquired a new stake in shares of Medpace during the fourth quarter worth approximately $31,000. Jones Financial Companies Lllp increased its stake in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after buying an additional 110 shares during the last quarter. Lindbrook Capital LLC raised its holdings in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after acquiring an additional 29 shares in the last quarter. Finally, Assetmark Inc. boosted its stake in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after acquiring an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Down 2.3 %

Shares of Medpace stock opened at $297.73 on Wednesday. Medpace Holdings, Inc. has a twelve month low of $289.01 and a twelve month high of $459.77. The stock has a market capitalization of $9.07 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 3.81 and a beta of 1.47. The business’s 50 day simple moving average is $334.26 and its 200-day simple moving average is $338.52.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

MEDP has been the subject of several research analyst reports. Leerink Partners started coverage on shares of Medpace in a research report on Monday, March 24th. They issued a “market perform” rating and a $330.00 target price for the company. Robert W. Baird boosted their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a report on Monday, March 24th. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus target price of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.